Voyager Therapeutics, Inc.
VYGR · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $40.4M | $80.0M | −49.5% |
| Operating income | −$132M | −$83.3M | −58.3% |
| Net income | −$120M | −$65.0M | −84.2% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $4.00M | $13.4M | −70.1% |
| Operating income | −$26.4M | −$30.6M | +13.7% |
| Net income | −$24.7M | −$27.9M | +11.5% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Voyager Therapeutics's revenue in FY2025?
- $40.4M in FY2025 (Fiscal year ended Dec 31, 2025), −49.5% vs $80.0M a year earlier, per its 10-K filed Mar 2026.
- Was Voyager Therapeutics profitable in FY2025?
- No: net income was −$120M and operating income −$132M in FY2025.
- What was Voyager Therapeutics's revenue in Q3 2026?
- $4.00M (−70.1% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.